SEC Filing Analysis: United Therapeutics Corp (UTHR)

Executive Summary

• Trading Significance: Low
• Key Takeaway: CEO Martine Rothblatt exercised options and sold shares worth ~$5M via a pre-arranged 10b5-1 plan.
• Market Impact: Negligible; transaction volume is minimal relative to the company's $23B valuation.

Company Information

Field	Value
Company	United Therapeutics Corp
Ticker Symbol	UTHR
CIK	0001082554
Industry	Pharmaceutical Preparations

Insider Information

Field	Value
Name	Martine A. Rothblatt
CIK	0001106578
Title/Position	Chairperson & CEO
Relationship	Director, Officer

Transaction Details

Field	Value
Form Type	4
Transaction Date	2026-03-24
Transaction Code	M (Exercise) & S (Sale)
Security Type	Common Stock
Shares Involved	9,500
Price Per Share	~$529.34 (Weighted Avg)
Total Value	~$5,028,776
Shares Owned After	40,513 (Direct)
Ownership Type	Direct & Indirect

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$5,028,776
% of Market Cap	0.02%
Shares Transacted	9,500
% of Shares Outstanding	0.02%
Post-Transaction Ownership	~680,000 shares (Total Control)
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: For a Large-Cap company ($23.07B), a $5M transaction is routine and immaterial to stock liquidity.
• Ownership Concentration: The insider retains significant indirect holdings (approx. 640k shares in trusts) and direct holdings, totaling ~1.55% of the company.
• Dilution Impact: The exercise of 9,500 options adds a negligible 0.02% to the share count, creating virtually no dilution pressure.
• Transaction Significance: Both value and volume metrics are well below the 0.1% threshold for significance.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: This is a classic "cashless exercise" where options are exercised and sold immediately. The sale was conducted under a 10b5-1 plan adopted in Nov 2025, removing speculative signaling.

Volume & Sentiment

• Expected Volume Impact: None. The 9,500 shares represent a tiny fraction of daily volume for a stock of this size.
• Sentiment Indicator: Neutral. Executives frequently exercise expiring options or diversify holdings via planned sales.

Additional Context

Transaction Notes

• Timing: The options exercised had an expiration date of March 2027, but were exercised early under the plan.
• Special Circumstances: The sales were executed pursuant to a Rule 10b5-1 trading plan adopted on November 7, 2025. The sales occurred in multiple tranches ranging from ~$516 to ~$536.
• Holdings: The reporting person has substantial indirect ownership through a spouse and various trusts.